Alvotech executives will participate in June investor conferences, discussing biosimilar developments. Webcasts available online.
Quiver AI Summary
Alvotech, a biotechnology company focused on the development of biosimilar medicines, announced that its Founder and Executive Chairman Robert Wessman, along with Chief Strategy Officer Dr. Balaji V. Prasad, will participate in several investor conferences in June 2026. These events include the Jefferies Global Healthcare Conference, the Goldman Sachs 47th Annual Global Healthcare Conference, and the UBS Virtual Generics and Biosimilars Day, with live audio webcasts accessible to the public. Alvotech, which has already approved and marketed five biosimilars globally, is working on nine additional biosimilar candidates targeting various diseases. The company aims to be a leader in the biosimilar industry by providing high-quality, cost-effective products supported by extensive in-house capabilities and strategic commercial partnerships across several regions.
Potential Positives
- Participation in multiple high-profile investor conferences demonstrates Alvotech's commitment to transparency and engagement with the investment community.
- The announcement of five approved and marketed biosimilars indicates a strong position in the competitive biosimilar market.
- The company's pipeline of nine disclosed biosimilar candidates emphasizes ongoing innovation and potential for future growth in various therapeutic areas.
- The formation of strategic commercial partnerships enhances Alvotech's global reach and market expertise, positioning the company for increased market penetration.
Potential Negatives
- Lack of specific details regarding any new products or breakthroughs during the investor conferences may lead to investor disappointment or skepticism about the company's growth prospects.
- Presence of key executives in multiple investor conferences in a short period may indicate heightened scrutiny or concerns from investors about the company's performance and future direction.
- Failure to disclose any financial performance metrics or updates in the press release could create uncertainty regarding the company's current financial health and market position.
FAQ
What are the upcoming investor conferences for Alvotech?
Alvotech will participate in the Jefferies Global Healthcare Conference, Goldman Sachs Healthcare Conference, and UBS Virtual Generics and Biosimilars Day.
Who will represent Alvotech at these conferences?
Robert Wessman, Founder and Executive Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will represent Alvotech.
How can I watch the live webcasts of the events?
The live audio webcasts can be accessed in the Investors Section of Alvotech’s website under News and Events.
How long will the event recordings be available?
Event recordings will be available for up to 90 days after the live sessions.
What biosimilars has Alvotech developed?
Alvotech has developed and marketed biosimilars for Humira®, Stelara®, Simponi®, Eylea®, and Prolia®/Xgeva®.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALVO Hedge Fund Activity
We have seen 36 institutional investors add shares of $ALVO stock to their portfolio, and 37 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 1,765,420 shares (+494.3%) to their portfolio in Q1 2026, for an estimated $6,055,390
- POINTSTATE CAPITAL LP removed 1,049,039 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $3,598,203
- OAKTREE CAPITAL MANAGEMENT LP removed 1,030,020 shares (-65.9%) from their portfolio in Q4 2025, for an estimated $5,284,002
- UBS GROUP AG added 186,097 shares (+136.8%) to their portfolio in Q1 2026, for an estimated $638,312
- NORGES BANK removed 180,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $923,400
- VANGUARD GROUP INC added 141,948 shares (+3.3%) to their portfolio in Q4 2025, for an estimated $728,193
- MARSHALL WACE, LLP removed 136,859 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $702,086
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$ALVO Price Targets
Multiple analysts have issued price targets for $ALVO recently. We have seen 2 analysts offer price targets for $ALVO in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Glen Santangelo from Barclays set a target price of $4.0 on 03/24/2026
- Ashwani Verma from UBS set a target price of $6.0 on 03/24/2026
Full Release
REYKJAVIK, Iceland, June 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Alvotech's Founder and Executive Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in June as follows:
- Jefferies Global Healthcare Conference in New York – fireside chat on Thursday, June 4, 2026 at 9:20 am ET
- Goldman Sachs 47 th Annual Global Healthcare Conference in Miami – fireside chat Monday, June 8, 2026 at 8:40 am ET
-
UBS Virtual Generics and Biosimilars Day
– fireside chat on Wednesday, June 10, 2026 at 10:30 am ET
The live audio webcasts will be available to investors and the general public and can be accessed in the Investors Section of Alvotech’s website under News and Events – Events and Presentations . After the event, a recording will also be available for up to 90 days.
For further information, contact:
Media
Benedikt Stefansson
Sarah MacLeod
[email protected]
Investors
Dr. Balaji V Prasad
Benedikt Stefansson
[email protected]
About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit
https://www.alvotech.com
. None of the information on the Alvotech website shall be deemed part of this press release.
For more information, please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram and YouTube .
